COLL vs. ADMA, ACLX, AKRO, RYTM, SRRK, IMVT, APLS, VKTX, ACAD, and CRNX
Should you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include ADMA Biologics (ADMA), Arcellx (ACLX), Akero Therapeutics (AKRO), Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), Immunovant (IMVT), Apellis Pharmaceuticals (APLS), Viking Therapeutics (VKTX), ACADIA Pharmaceuticals (ACAD), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry.
Collegium Pharmaceutical vs.
Collegium Pharmaceutical (NASDAQ:COLL) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations, valuation and community ranking.
ADMA Biologics received 26 more outperform votes than Collegium Pharmaceutical when rated by MarketBeat users. Likewise, 72.08% of users gave ADMA Biologics an outperform vote while only 65.26% of users gave Collegium Pharmaceutical an outperform vote.
75.7% of ADMA Biologics shares are held by institutional investors. 4.0% of Collegium Pharmaceutical shares are held by insiders. Comparatively, 3.7% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
ADMA Biologics has a net margin of 17.80% compared to Collegium Pharmaceutical's net margin of 14.78%. Collegium Pharmaceutical's return on equity of 104.67% beat ADMA Biologics' return on equity.
Collegium Pharmaceutical presently has a consensus target price of $43.60, suggesting a potential upside of 49.67%. ADMA Biologics has a consensus target price of $21.25, suggesting a potential upside of 34.15%. Given Collegium Pharmaceutical's higher probable upside, analysts clearly believe Collegium Pharmaceutical is more favorable than ADMA Biologics.
In the previous week, ADMA Biologics had 1 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 5 mentions for ADMA Biologics and 4 mentions for Collegium Pharmaceutical. ADMA Biologics' average media sentiment score of 0.94 beat Collegium Pharmaceutical's score of 0.70 indicating that ADMA Biologics is being referred to more favorably in the news media.
Collegium Pharmaceutical has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500.
Collegium Pharmaceutical has higher revenue and earnings than ADMA Biologics. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.
Summary
ADMA Biologics beats Collegium Pharmaceutical on 11 of the 19 factors compared between the two stocks.
Get Collegium Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Collegium Pharmaceutical Competitors List
Related Companies and Tools
This page (NASDAQ:COLL) was last updated on 2/21/2025 by MarketBeat.com Staff
